Rodino-Klapac Louise
SEC CIK 1836218 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| SRPT | Sarepta Therapeutics, Inc. | Pres, R, D, Tech Ops | 203.9K | $299.9K | — | 32 | 2021-11-16 | 2026-09-04 |
Most active insiders at SRPT, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Estepan Ian Michael | COO | — | $294.2K |
| 2 | Mayo Stephen | Dir | — | $123.2K |
| 3 | Wong Ryan Ho-Yan | CFO | — | — |
| 4 | Rothfuss Cristin | EVP, GC | — | — |
| 5 | Chambers Michael Andrew | Dir | — | — |
| 6 | Rodino-Klapac Louise | Pres, R, D, Tech Ops | — | — |
| 7 | Boor Kathryn Jean | Dir | — | — |
| 8 | Nicaise Claude | Dir | — | — |
| 9 | SEVERINO MICHAEL | CEO, Dir | — | — |
| 10 | Barry Richard | Dir | — | — |
Transactions 32
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-08 20:01 | 2026-09-04 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | Pres, R, D, Tech Ops | F - Tax | $22.22 | -21.4K | 203.9K | -10% | -$476.0K | |
| 2026-03-13 | 2026-03-11 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | Pres, R, D, Tech Ops | F - Tax | $17.03 | -948 | 225.3K | -0.4% | -$16.1K | |
| M | 2026-03-11 | 2026-03-09 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | Pres, R, D, Tech Ops | F - Tax | $16.95 | -1,399 | 227.2K | -0.6% | -$23.7K |
| DM | 2026-03-03 | 2026-03-02 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | Pres, R, D, Tech Ops | F - Tax | $16.20 | -4,485 | 228.4K | -2% | -$72.7K |
| D | 2026-03-03 | 2026-03-01 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | Pres, R, D, Tech Ops | M - OptEx | — | +8,125 | 232.2K | +4% | — |
| 2025-11-19 | 2025-11-17 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | Pres, R, D, Tech Ops | F - Tax | $18.42 | -4,582 | 224.0K | -2% | -$84.4K | |
| M | 2025-09-05 | 2025-09-03 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | Pres, R, D, Tech Ops | A - Grant | $0.00 | +143.9K | 228.6K | +170% | $0 |
| DM | 2025-03-11 | 2025-03-10 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | F - Tax | $100.13 | -3,463 | 76.4K | -4% | -$346.8K |
| D | 2025-03-11 | 2025-03-10 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | A - Grant | — | +8,276 | 84.6K | +11% | — |
| D | 2025-03-11 | 2025-03-07 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | M - OptEx | — | +5,500 | 79.8K | +7% | — |
| DM | 2025-03-10 | 2025-03-07 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | F - Tax | $103.70 | -8,504 | 82.3K | -9% | -$881.9K |
| D | 2025-03-10 | 2025-03-06 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | M - OptEx | — | +17.5K | 82.8K | +27% | — |
| 2025-03-06 | 2025-03-04 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | F - Tax | $101.34 | -1,704 | 65.3K | -3% | -$172.7K | |
| 2025-03-04 | 2025-03-03 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | F - Tax | $103.77 | -715 | 67.0K | -1% | -$74.2K | |
| 2024-11-20 | 2024-11-18 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | F - Tax | $102.89 | -4,558 | 67.6K | -6% | -$469.0K | |
| D | 2024-06-25 | 2024-06-24 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | F - Tax | $164.64 | -2,182 | 72.1K | -3% | -$359.2K |
| D | 2024-06-25 | 2024-06-21 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | M - OptEx | — | +6,250 | 74.3K | +9% | — |
| M | 2024-03-11 | 2024-03-07+ | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | F - Tax | $122.19 | -1,421 | 68.1K | -2% | -$173.6K |
| 2024-03-06 | 2024-03-04 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | F - Tax | $125.32 | -1,728 | 69.5K | -2% | -$216.6K | |
| D | 2024-03-05 | 2024-03-01 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | A - Grant | $0.00 | +6,000 | 71.2K | +9% | $0 |
| D | 2024-03-05 | 2024-03-01 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | F - Tax | $126.19 | -778 | 65.2K | -1% | -$98.2K |
| 2023-11-20 | 2023-11-17 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | F - Tax | $82.98 | -4,508 | 65.8K | -6% | -$374.1K | |
| 2023-03-10 | 2023-03-08 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | F - Tax | $153.19 | -912 | 70.2K | -1% | -$139.7K | |
| D | 2023-03-08 | 2023-03-06 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | A - Grant | $0.00 | +4,500 | 71.1K | +7% | $0 |
| D | 2023-03-08 | 2023-03-06 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | F - Tax | $157.21 | -1,134 | 66.6K | -2% | -$178.3K |
| 2023-03-03 | 2023-03-01 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | F - Tax | $147.57 | -522 | 67.7K | -0.8% | -$77.0K | |
| 2022-11-21 | 2022-11-17 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | F - Tax | $108.52 | -4,211 | 68.0K | -6% | -$457.0K | |
| D | 2022-03-08 | 2022-03-07 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | A - Grant | $0.00 | +8,000 | 72.1K | +12% | $0 |
| D | 2022-03-08 | 2022-03-04 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | F - Tax | $79.20 | -1,216 | 64.1K | -2% | -$96.3K |
| 2022-03-01 | 2022-03-01 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | F - Tax | $75.05 | -572 | 65.3K | -0.9% | -$42.9K | |
| 2021-11-29 | 2021-11-24 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO, Head of R, D | P - Purchase | $79.33 | +3,780 | 65.7K | +6% | +$299.9K | |
| 2021-11-17 | 2021-11-16 | SRPT | Sarepta Therapeutics, Inc. | Rodino-Klapac Louise | CSO | A - Grant | $0.00 | +40.0K | 61.9K | +183% | $0 |
Purchase Sale Sale after option exercise All abbreviations